FDA Investigator John D White
John D White has inspections in 11 countries as of 11 Oct 2023. John D White has collaborated with a combined 3021 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
25
Last Inspection Date:
11 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United Kingdom of Great Britain and Northern Ireland,
China,
United States of America,
Italy,
Germany,
Japan,
Canada,
France,
Australia,
Ireland
Co-Investigator(s):
A Williams,
Alan P Kurtzberg,
Alberto A Viciedo,
Angela E Glenn,
Anh M Lac,
Anita Narula, PhD,
Ann L Demarco,
Anthony A Charity,
Arthur T Ogdahl,
Azza Talaat,
Barbara J Rincon,
Bijoy Panicker,
Bo Chi, PhD,
Bonita S Chester,
Brenda W Uratani, PhD,
Brooke K Higgins,
Candido Torres,
Carl A Huffman, III,
Carl Lee,
Carolyn E Barney,
CDR Rochelle B Young, RPh, MSA,
Charles M Edwards,
Charles R Cote, RIC,
Chiang Syin, PhD,
Christopher Downey, PhD,
Christopher S Keating,
Constantin Y Philopoulos,
Cynthia J Lee, MS,
Dawn E Barkans,
Denise M Digiulio,
Dennis Cantellops Paite,
Devaughn Edwards,
Diane L Raccasi,
Doan T Nguyen, PharmD,
Donald C Obenhuber, PhD,
Donald L Lech,
Dr. Chunchang Fang,
Dr. Ralph M Bernstein, PhD,
Dr. Robert C Horan, MD,
Dr. Willie F Vann, PhD,
Edecia A Richards,
Eliezar Ramos,
Elizabeth B Griffin,
Erika E Englund, PhD,
Erika V Butler,
Evaughn Edwards,
Felix Maldonado,
Garry H Stewart,
George Pyramides,
Ivis Lnegron Torres,
James C Maclaughlin,
James I Giefer,
James R Birkenstamm,
James W Leonette,
James W Plucinski,
Jeffrey A Sommers,
Jeffrey D Meng,
Jennifer J Stone,
Jennifer L Huntington,
Jonathan W Chapman,
Jorge L Gonzalez,
Jorge L Guadalupe,
Jose Alopez Rubet,
Jose R Hernandez,
Joyce A Kellett,
Julie D Bringger,
Justin A Boyd,
Kalavati Suvarna, PhD,
Kara D Dobbin,
Karyn M Campbell,
Katherine Szestypalow,
Kathleen R Jones, PhD,
Kevin A Gonzalez,
Kevin D Kallander,
Khoa Nathanv Tran,
Kristen D Evans,
Kurt A Brorson, PhD,
Larry K Austin,
Latorie S Jones,
LCDR Wilfred A Darang,
Loretta Nemchik,
Luella J Rossi,
Luis A Dasta,
Margaret M Annes,
Mariza M Jafary,
Mark Brunswick, PhD,
Mark E Parmon,
Mark P Prusak,
Mary E Storch,
Matthew B Casale,
Megan A Haggerty,
Michael A Charles,
Michael A Taylor,
Michael K Larson,
Michael L Chasey,
Michael R Goga,
Michael Shanks, MS,
Michelle D Haamid,
Michelle M Noe,
Michelle Y Clark Stuart,
Mihaly S Ligmond,
Milos Dokmanovic, PhD,
Monica Commerford, PhD,
Mra Munizn,
Nasir Ali, PhD,
Noreen Muniz,
Omotunde O Osunsanmi,
Patrick C Klotzbuecher,
Paul M Kawamoto,
Peter E Baker,
Philip F Istafanos, DMV, MS,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Reba A Gates,
Regina T Brown,
Reyes Candau Chacon, PhD,
Richard E Needham,
Richard J Friedman,
Richard L Rutherford,
Richard Ledwidge (nmi), PhD,
Richard W Berning,
Robert C Horu, PhD,
Robert D Tollefsen,
Robert J Martin,
Robert W Jennings,
Rochelle K Kimmel,
Roger F Zabinski,
Rose M Ashley,
Sarah E Mcmullen,
Scott T Ballard,
Sharon K Thoma, PharmD,
Simone E Pitts,
Stephen J Koniers,
Steven M Weinman,
Susan F Laska, MS,
Susan W Ting,
Syed N Ali,
Tamara Brey,
Tania K Mercado,
Temar Q Williams,
Teresa C Thompson,
Teresa I Navas,
Teresa Jimenez,
Terri L Dodds,
Thomas E Friel,
Thomas H Jenkins,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Torrance J Slayton,
Veronica Fuentes, MS,
Victor Spanioli,
Virgilio F Pacio, CSO,
Walter N Lange,
Wayne D Mcgrath,
Wayne E Seifert,
Yanming An, PhD,
Yasamin Ameri,
Yvette I Johnson,
Zedong Dong,
Zerita White,
Zhihao Qiu (Peter), PhD,
Zhong Li, PhD,
Ziyang Su, PhD
John D White's Documents
Publish Date | Document Type | Title |
---|---|---|
September, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-09-16 |
September, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-09-18 |
September, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-09-16 |
April, 2003 | EIR | Kyowa Hakko Kirin Co., Ltd. - EIR, 2003-04-03 |
April, 2003 | FDA 483 | KAKEN Pharmaceutical Co., LTD - Form 483, 2003-04-10 |
September, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-09-18 |
April, 2003 | FDA 483 Response | Kyowa Hakko Kirin Co., Ltd. - Form 483R, 2003-06-20 |
September, 2003 | FDA 483 | PRIMED INSTRUMENTS INC - Form 483, 2003-09-17 |
May, 2001 | FDA 483 | Jiangsu Hengrui Medicine Co., Ltd. - Form 483, 2001-05-25 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more